Page last updated: 2024-11-05

methohexital

Description Research Excerpts Clinical Trials Roles Classes Pathways Study Profile Bioassays Related Drugs Related Conditions Protein Interactions Research Growth Market Indicators

Description

Methohexital: An intravenous anesthetic with a short duration of action that may be used for induction of anesthesia. [Medical Subject Headings (MeSH), National Library of Medicine, extracted Dec-2023]

methohexital : A barbiturate, the structure of which is that of barbituric acid substituted at N-1 by a methyl group and at C-5 by allyl and 1-methylpent-2-ynyl groups. [Chemical Entities of Biological Interest (ChEBI), Hastings J, Owen G, Dekker A, Ennis M, Kale N, Muthukrishnan V, Turner S, Swainston N, Mendes P, Steinbeck C. (2016). ChEBI in 2016: Improved services and an expanding collection of metabolites. Nucleic Acids Res]

Cross-References

ID SourceID
PubMed CID9034
CHEMBL ID7413
CHEBI ID102216
SCHEMBL ID80729
MeSH IDM0013589

Synonyms (73)

Synonym
1-methyl-5-(1-methylpent-2-yn-1-yl)-5-prop-2-en-1-ylpyrimidine-2,4,6(1h,3h,5h)-trione
.alpha.-dl-1-methyl-5-allyl-5-(1'-methylpentyn-2-yl)barbituric acid
barbituric acid, 5-allyl-1-methyl-5-(1-methyl-2-pentynyl)-, (.+/-.)-
methohexital (usp/inn)
D04985
151-83-7
C07844
methohexital
(+/-)-5-allyl-1-methyl-5-(1-methyl-2-pentynyl)barbituric acid
alpha-dl-1-methyl-5-allyl-5-(1'-methylpentyn-2-yl)barbituric acid
methohexitone
5-allyl-1-methyl-5-(1-methyl-2-pentynyl)-2,4,6(1h,3h,5h)-pyrimidinetrione
DB00474
5-allyl-1-methyl-5-(1-methyl-pent-2-ynyl)-pyrimidine-2,4,6-trione
5-allyl-5-(3-hexyn-2-yl)-1-methylbarbituric acid
18652-93-2
2,4,6(1h,3h,5h)-pyrimidinetrione, 1-methyl-5-(1-methyl-2-pentynyl)-5-(2-propenyl)-, (+/-)-
5-hex-3-yn-2-yl-1-methyl-5-prop-2-enyl-1,3-diazinane-2,4,6-trione
methohexital civ
CHEMBL7413
CHEBI:102216 ,
(+-)-5-allyl-1-methyl-5-(1-methyl-2-pentynyl)barbituric acid
methohexitalum
metohexital
1-methyl-5-(1-methylpent-2-yn-1-yl)-5-(prop-2-en-1-yl)pyrimidine-2,4,6(1h,3h,5h)-trione
A809228
compound 25398
metoesital [dcit]
methodrexitone
compound 22451
enallynymall
e5b8nd5ipe ,
methohexital [usp:inn:ban]
2,4,6(1h,3h,5h)-pyrimidinetrione, 1-methyl-5-(1-methyl-2-pentynyl)-5-(2-propenyl)-, (+-)-
einecs 205-798-6
metohexital [inn-spanish]
methohexitalum [inn-latin]
unii-e5b8nd5ipe
enallynymalum
barbituric acid, 5-allyl-1-methyl-5-(1-methyl-2-pentynyl)-
metoesital
5-allyl-5-(hex-3-yn-2-yl)-1-methylpyrimidine-2,4,6(1h,3h,5h)-trione
EPITOPE ID:117125
gtpl7233
5-(hex-3-yn-2-yl)-6-hydroxy-3-methyl-5-(prop-2-en-1-yl)-2,3,4,5-tetrahydropyrimidine-2,4-dione
methohexital [who-dd]
methohexital [vandf]
methohexital [mart.]
methohexital civ [usp-rs]
methohexital [inn]
methohexital [mi]
methohexital [usp monograph]
SCHEMBL80729
1-methyl-5-(1-methyl-2-pentynyl)-5-allyl-barbituric acid
NZXKDOXHBHYTKP-UHFFFAOYSA-N
2,4,6(1h,3h,5h)-pyrimidinetrione, 1-methyl-5-(1-methyl-2-pentynyl)-5-(2-propenyl)-, (.+/-.)-
2,4,6(1h,3h,5h)-pyrimidinetrione, 1-methyl-5-(1-methyl-2-pentynyl)-5-(2-propenyl)-
DTXSID1023287 ,
5-(hex-3-yn-2-yl)-1-methyl-5-(prop-2-en-1-yl)-1,3-diazinane-2,4,6-trione
methohexital 1.0 mg/ml in methanol
dl-1-methyl-5-(1-methyl-2-pentynyl)-5-(2-propenyl)-2,4,6(1h,3h,5h)-pyrimidinetrione
Q851813
BM164664
2,4(3h,5h)-pyrimidinedione, 6-hydroxy-3-methyl-5-(1-methyl-2-pentyn-1-yl)-5-(2-propen-1-yl)-
methohexital (usp monograph)
methohexital (usp:inn:ban)
metohexital (inn-spanish)
methohexital (mart.)
methohexitalum (inn-latin)
dtxcid903287
n01af01
n05ca15
methohexital civ (usp-rs)

Research Excerpts

Overview

Methohexital is a short-acting barbiturate used for procedural sedation in the emergency department (ED) It is a safe and reliable method of activating epileptogenic foci during acute ECoG recordings. Methohexitals is a useful alternative to thiobarbiturates for short-duration barbituries in Greyhounds.

ExcerptReferenceRelevance
"Methohexital is a safe and effective option for procedural sedation for musculoskeletal procedures in the ED when compared with ketamine and propofol."( A Safety Comparison of Single-Agent Methohexital, Ketamine, or Propofol for Musculoskeletal Procedural Sedation in the Emergency Department.
Kruggel, S; Mishler, A; Sullivan, L, 2022
)
2.44
"Methohexital is a short-acting barbiturate used for procedural sedation in the emergency department (ED). "( Methohexital-Induced Seizure in a Patient Undergoing Conscious Sedation.
Bisanz, B; Clark, RF; Parathasarathy, V; Trumm, N; Willeford, A, 2020
)
3.44
"Methohexital is a common anesthetic agent used for electroconvulsive therapy. "( Methohexital-induced seizures during electroconvulsive therapy.
Rasmussen, KG; Swintak, CC; Vande Voort, JL; Wall, CA, 2013
)
3.28
"Methohexital would seem to be a useful adjunct drug for the performance of these procedures because of its well-known attributes (eg, rapid induction and recovery, brief duration, and minimal hemodynamic changes)."( Methohexital for orthopaedic procedures in the emergency department.
Bono, JV; Reilly, KM; Rella, JG; Zink, BJ, 1993
)
2.45
"Methohexital is an ultrashort-acting barbiturate widely used in dentistry because of its rapid onset, predictable effects, and short duration of action. "( Methohexital: a practical review for outpatient dental anesthesia.
Martone, CH; Nagelhout, J; Wolf, SM,
)
3.02
"Methohexital is a safe and reliable method of activating epileptogenic foci during acute ECoG recordings and can decrease the time for ECoG recordings during surgery."( Methohexital activation of epileptogenic foci during acute electrocorticography.
Atkinson, RA; Hermann, BP; Richey, ET; Wyler, AR,
)
2.3
"Methohexital is a useful alternative to thiobarbiturates for short-duration barbiturate anesthesia in Greyhounds."( Barbiturate anesthesia in greyhound and mixed-breed dogs: comparative cardiopulmonary effects, anesthetic effects, and recovery rates.
Muir, WW; Robinson, EP; Sams, RA, 1986
)
0.99

Effects

Methohexital has been used for procedural sedation in the emergency department, but its use for endotracheal intubation in intensive care units has not been studied. It has a high efficacy rate for sleep (85%) or sedation (96%)

ExcerptReferenceRelevance
"Methohexital has a high efficacy rate for sleep (85%) or sedation (96%), and has a relatively rapid onset."( A prospective study of rectal methohexital: efficacy and side effects in 648 cases.
Audenaert, SM; Montgomery, CL; Sutherland, J; Thompson, DE, 1995
)
1.3
"Methohexital has replaced amobarbital during Wada testing at many centers. "( Language assessment in Wada test: comparison of methohexital and amobarbital.
Alexopoulos, AV; Dinner, DS; Kim, H; Kotagal, P; Loddenkemper, T; Lüders, HO; Möddel, G; Schuele, SU, 2009
)
2.05
"Methohexital has been used for procedural sedation in the emergency department, but its use for endotracheal intubation in intensive care units has not been studied."( A comparison of methohexital versus etomidate for endotracheal intubation of critically ill patients.
Arroliga, AC; Bauer, SR; Diaz-Guzman, E; Heresi, GA; Mireles-Cabodevila, E, 2010
)
2.15
"Methohexital has been demonstrated to be the anexthesia of safety and choice for ECT when compared to diazepam."( Drug modification of ECT: methohexital and diazepam. II.
Allen, RE; Pitts, FN; Summers, WK, 1980
)
1.28
"Methohexital has a high efficacy rate for sleep (85%) or sedation (96%), and has a relatively rapid onset."( A prospective study of rectal methohexital: efficacy and side effects in 648 cases.
Audenaert, SM; Montgomery, CL; Sutherland, J; Thompson, DE, 1995
)
1.3
"Methohexital and propofol have been shown to be effective agents for continuous intravenous infusion to produce conscious sedation during oral surgical procedures. "( Comparison of propofol and methohexital continuous infusion techniques for conscious sedation.
Buckley, MJ; Herlich, A; Johns, FR; Sandler, NA, 1998
)
2.04
"Methohexital has little or no influence on cortisol levels."( [Changes in expression of lymphocyte surface markers following administration of etomidate, midazolam or methohexital].
Beck, D; Crozier, TA; Kettler, D; Schuff-Werner, P, 1987
)
1.21

Actions

ExcerptReferenceRelevance
"Methohexital seemed to inhibit hexokinase activity by solubilizing the mitochondrial bound form."( [Mechanisms of the protective effect of methohexital on cerebral energy metabolism].
Hanke, J; Krieglstein, J, 1982
)
1.25

Treatment

Methohexital treatment reduced infarct volumes by 32%, 71%, and 66%, respectively, compared with normothermic controls. Treatment reduced both the osmotic water flow and vasopressin-induced alterations of membrane structure to the same extent.

ExcerptReferenceRelevance
"Methohexital treatment, mild hypothermia, and mild hypothermia plus methohexital treatment reduced infarct volumes by 32%, 71%, and 66%, respectively, compared with normothermic controls."( No additional neuroprotection provided by barbiturate-induced burst suppression under mild hypothermic conditions in rats subjected to reversible focal ischemia.
Baethmann, A; Schmid-Elsaesser, R; Steiger, HJ; Westermaier, T; Zausinger, S, 2000
)
1.03
"Methohexital treatment of the vasopressin-stimulated toad bladder reduced both the osmotic water flow and vasopressin-induced alterations of membrane structure to the same extent."( Relationship of aggregated intramembranous particles to water permeability in vasopressin-treated toad urinary bladder.
Di Scala, VA; Hays, RM; Kachadorian, WA; Levine, SD; Wade, JB, 1977
)
0.98

Toxicity

Methohexital is a safe and effective option for procedural sedation for musculoskeletal procedures in the ED. It is less frequently used due to concerns for adverse events associated with this drug class.

ExcerptReferenceRelevance
"MTX, when used by trained personnel who adhere to an established protocol, appears to be a safe and effective drug in selected ED patients."( The efficacy and safety of methohexital in the emergency department.
Darfler, K; Reilly, KM; Salluzzo, RF; Zink, BJ, 1991
)
0.58
"Our experience indicates that MHX, with appropriate monitoring as described here, is a safe and effective agent for use in pediatric oncology outpatient sedation programs."( Brief unconscious sedation for painful pediatric oncology procedures. Intravenous methohexital with appropriate monitoring is safe and effective.
Axtell, RA; Fahner, JB; Freyer, DR; Hackbarth, RM; Hassan, NE; Kopec, JS; Sanfilippo, DJ; Schwanda, AE; Waskerwitz, MJ, 1993
)
0.51
" Pharmacological strategies used in outpatient dental settings must be both safe and effective."( Comparing efficacy and safety of four intravenous sedation regimens in dental outpatients.
Beirne, OR; Dionne, RA; Gonty, A; Moore, PA; Yagiela, JA; Zuniga, J, 2001
)
0.31
"These data provide evidence that the drugs and doses evaluated resulted in therapeutic benefit to dental outpatients, with minimal incidence of potentially serious adverse effects."( Comparing efficacy and safety of four intravenous sedation regimens in dental outpatients.
Beirne, OR; Dionne, RA; Gonty, A; Moore, PA; Yagiela, JA; Zuniga, J, 2001
)
0.31
"5 million adverse drug reaction (ADR) reports for 8620 drugs/biologics that are listed for 1191 Coding Symbols for Thesaurus of Adverse Reaction (COSTAR) terms of adverse effects."( Assessment of the health effects of chemicals in humans: II. Construction of an adverse effects database for QSAR modeling.
Benz, RD; Contrera, JF; Kruhlak, NL; Matthews, EJ; Weaver, JL, 2004
)
0.32
" Safety was examined by reviewing the occurrence of minor and major adverse effects during esophagogastroduodenoscopy sedation."( The safety of propofol sedation for elective nonintubated esophagogastroduodenoscopy in pediatric patients.
Cloney, DL; Cornelius, K; Davis, AT; Fitzgerald, RK; Hackbarth, RM; Hassan, NE; Kopec, JS; McCullough, A; Ndika, AN; Rajasekaran, S; Sanfilippo, D, 2014
)
0.4
" These data suggest that propofol is a safe and effective agent for esophagogastroduodenoscopy sedation."( The safety of propofol sedation for elective nonintubated esophagogastroduodenoscopy in pediatric patients.
Cloney, DL; Cornelius, K; Davis, AT; Fitzgerald, RK; Hackbarth, RM; Hassan, NE; Kopec, JS; McCullough, A; Ndika, AN; Rajasekaran, S; Sanfilippo, D, 2014
)
0.4
" Methohexital, a barbiturate, is less frequently used due to concerns for adverse events associated with this drug class."( A Safety Comparison of Single-Agent Methohexital, Ketamine, or Propofol for Musculoskeletal Procedural Sedation in the Emergency Department.
Kruggel, S; Mishler, A; Sullivan, L, 2022
)
1.91
" Overall adverse events occurred in 34."( A Safety Comparison of Single-Agent Methohexital, Ketamine, or Propofol for Musculoskeletal Procedural Sedation in the Emergency Department.
Kruggel, S; Mishler, A; Sullivan, L, 2022
)
1
"Methohexital is a safe and effective option for procedural sedation for musculoskeletal procedures in the ED when compared with ketamine and propofol."( A Safety Comparison of Single-Agent Methohexital, Ketamine, or Propofol for Musculoskeletal Procedural Sedation in the Emergency Department.
Kruggel, S; Mishler, A; Sullivan, L, 2022
)
2.44
"Due to longer procedure duration and an unfavorable side effect profile, etomidate appears inferior to methohexital as an anesthetic agent in mECT despite longer seizure durations."( Comparison of etomidate and methohexital as anesthetic agents for continuation and maintenance electroconvulsive therapy: A retrospective analysis of seizure quality and safety.
Baldinger-Melich, P; Eder, V; Frey, R; Kress, HG; Michalek-Sauberer, A; Millischer, V; Pramhas, S; Rujescu, D; Wiedermann, I, 2023
)
1.42

Pharmacokinetics

The aim of the present experiments was to establish the influence of methohexital on the plasma concentrations and pharmacokinetic parameters of lidocaine in rabbits. The study included patients undergoing upper abdominal surgery and orthopaedic patients under general anaesthesia.

ExcerptReferenceRelevance
" The terminal elimination half-life of the drug is relatively short (70-125 min), which is a result of a high metabolic clearance rate (657-999 ml plasma/min)."( Pharmacokinetics of methohexitone following intravenous infusion in humans.
Breimer, DD, 1976
)
0.26
"A nonlinear pharmacokinetic model was constructed to describe the body distribution of intravenous anesthetics, using the physiological modeling approach for drug distribution kinetics."( Nonlinear pharmacokinetic model of intravenous anesthesia.
DeAngelis, RJ; Gillis, PP; Wynn, RL, 1976
)
0.26
"The pharmacokinetic characteristics of a constant rate methohexitone infusion were studied in young ASA 1 patients undergoing maxillofacial surgery."( [Pharmacokinetics of methohexital given by constant rate intravenous infusion].
Bally, B; Gavend, M; Payen, JF; Serre-Debeauvais, F; Stieglitz, P; Tranchand, B, 1992
)
0.6
" The pharmacokinetic data obtained were compared with those from vascular surgery without cardiopulmonary bypass."( Pharmacokinetics of methohexital during cardiovascular surgery with cardiopulmonary bypass.
Boulieu, R; Ferry, S; Foussadier, A; Lehot, JJ, 1991
)
0.6
"The pharmacokinetic profile of methohexital was studied in cirrhotic patients (n = 8), patients undergoing upper abdominal surgery (n = 8) and orthopaedic patients under general anaesthesia (n = 8)."( Effect of upper abdominal surgery and cirrhosis upon the pharmacokinetics of methohexital.
Bertrand, F; Chauvin, M; Duvaldestin, P; Farinotti, R; Karolak, FT; Lebrault, C, 1991
)
0.8
" The mean elimination half-life of methohexitone was 193 +/- 75 min; that is, considerably longer than previously reported for children, but in good agreement with findings in adults."( Pharmacokinetics of i.v. and rectal methohexitone in children.
Björkman, S; Corbey, M; Gabrielsson, J; Quaynor, H, 1987
)
0.27
" Anesthesia (combined with surgery) and increase in age did not separately affect the kinetics of the drug; however, the elimination half-life was longer in the elderly patients group than in the young non-anesthetized volunteers."( The pharmacokinetics of methohexital in young and elderly subjects.
Chiang, CK; Dhanaraj, J; Ghoneim, MM; Lilburn, JK; Schoenwald, RD, 1985
)
0.58
"5 min) was followed by an elimination phase (elimination half-life t 1/2 lambda z; 26."( Pharmacokinetics of intravenous and intramuscular methohexitone in dogs.
Kergueris, MF; Larousse, C; Lasserre, MP; Le Normand, Y; Meignier, M; Pinaud, M; Souron, R, 1984
)
0.27
" No significant correlations with temperature were found for other pharmacokinetic parameters."( Endotoxin-induced fever increases the clearance of methohexitone in rabbits.
Björkman, S; Redke, F, 1994
)
0.29
" When comparing HCPB and NCPB groups, elimination half-life (T1/2), TBC, volume of distribution (VD), area under the curve (AUC), and mean residence time (MRT) were similar."( Comparison of the pharmacokinetics of methohexital during cardiac surgery with cardiopulmonary bypass and vascular surgery.
Boulieu, R; Chassignolle, J; Clerc, J; Estanove, S; Ferry, S; Foussadier, A; George, M; Lehot, JJ; Villard, J, 1993
)
0.56
" Marker dispositions were described by recirculatory pharmacokinetic models based on very frequent early, and less frequent later, arterial blood samples."( Isoflurane alters the recirculatory pharmacokinetics of physiologic markers.
Avram, MJ; Enders-Klein, C; Henthorn, TK; Krejcie, TC; Niemann, CU; Shanks, CA, 2000
)
0.31
" The use of ketamine as an anaesthetic agent in rabbits is questionable, while the use of fentanyl in pigs, methohexitone in rats and ketamine in rats and pigs is well supported by the pharmacokinetic data."( Clearance of fentanyl, alfentanil, methohexitone, thiopentone and ketamine in relation to estimated hepatic blood flow in several animal species: application to prediction of clearance in man.
Björkman, S; Redke, F, 2000
)
0.31
" The aim of the present experiments was to establish the influence of methohexital on the plasma concentrations and pharmacokinetic parameters of lidocaine in rabbits."( The influence of methohexital on plasma concentration and pharmacokinetic parameters of lidocaine in rabbits.
Orszulak-Michalak, D; Owczarek, J; Wiktorowska-Owczarek, AK, 2004
)
0.9
" pharmacokinetic data on 670 drugs representing, to our knowledge, the largest publicly available set of human clinical pharmacokinetic data."( Trend analysis of a database of intravenous pharmacokinetic parameters in humans for 670 drug compounds.
Lombardo, F; Obach, RS; Waters, NJ, 2008
)
0.35

Compound-Compound Interactions

ExcerptReferenceRelevance
" First, propofol infusion was compared to thiopentone combined with midazolam."( Total intravenous anaesthesia for direct laryngoscopy: propofol infusion compared to thiopentone combined with midazolam and methohexitone infusion.
Clausen, TG; Halck, S; Munksgaard, A; Sonne, NM; Valentin, N, 1992
)
0.28

Bioavailability

ExcerptReferenceRelevance
" The mean bioavailability of methohexitone administered per rectum was 17%, with a six-fold variation between individuals."( Pharmacokinetics of i.v. and rectal methohexitone in children.
Björkman, S; Corbey, M; Gabrielsson, J; Quaynor, H, 1987
)
0.27
" Also there is no evidence as yet, that patients with liver disease and without a collateral portal circulation do have an increased bioavailability of oral high clearance drugs."( [Drug metabolism in patients with liver disease (author's transl)].
Epping, J; Fuchshofen-Röckel, M; Heusler, H; Richter, E; Zilly, W, 1980
)
0.26
" The bioavailability of the rectal gel appears sufficient to provide efficient clinical plasmatic concentrations."( [Pharmacokinetic and clinical evaluation of rectal hydrophilic gel of methohexital in pediatric surgery].
Benoit, I; Grellet, J; Merlet, JP; Meynat, Y; Michel-Guéroult, P; Saux, MC,
)
0.37

Dosage Studied

Methohexital for ECT showed a great variability, exceeding as well as undershooting the dosage recommendations widely. In animals initially anesthetized with pentobarbital, delta-9-THC over a wide dosage range produced only an enhancement of the reflex.

ExcerptRelevanceReference
"2 x 10(-6) M) displaced the dose-response curve for tetraethylammonium-methohexitone-induced contractures to the right."( Contractures elicited by tetraethylammonium in avian muscle treated with methohexitone.
Elliott, RC, 1979
)
0.26
" When Althesin was required in high total dosage (exceeding 150 mu1/kg), the immediate awakening was associated with emotional upset and confusion."( A study of cumulative effects and recovery from anaesthesia with intermittent doses of althesin. A comparison with methohexitone.
Kauste, A, 1976
)
0.26
" The etomidate dosage chosen more often gave an immediate satisfactory sleep."( A comparative study of etomidate and methohexital as induction agents for analgesic anesthesia.
Bastenier-Geens, J; Dubois-Primo, J; Genicot, C; Rucquoi, M, 1976
)
0.53
"Pentazocine, a systemic analgesic, can be utilized in local analgesic and intravenous techniques to provide better operating conditions in difficult cases, a reduction in the dosage of other agents employed, and a smoother recovery period."( The value of associating pentazocine with drugs used in accepted intravenous techniques.
Armstrong, PJ, 1975
)
0.25
" The doses of the anasthetic agents were selected from the dose-response experiments."( Effect of lithium and rubidium on the sleeping time caused by various intravenous anaesthetics in the mouse.
Männistö, PT; Saarnivaara, L, 1976
)
0.26
" In all three cases, an increase in the anesthetic (or equivalent medication) dosage prior to ECT prevented the emergence of postictal excitement at subsequent treatments."( Use of increased anesthetic dose prior to electroconvulsive therapy to prevent postictal excitement.
Devanand, DP; Sackeim, HA, 1992
)
0.28
" A study form was completed that provided data on dosage and response, indications for use, final diagnosis, hemodynamic and respiratory parameters, and an efficacy survey."( The efficacy and safety of methohexital in the emergency department.
Darfler, K; Reilly, KM; Salluzzo, RF; Zink, BJ, 1991
)
0.58
"The authors evaluated the sigmoidal administration of methohexital, the effect of methohexital concentration (1% versus 2%), the effect of dosage (25 mg/kg versus 15 mg/kg) on sleep-success rate, administration - sleep time, recovery time and the effect of aspirating the residual methohexital on recovery time."( Induction of anesthesia in children following administration of methohexital into the sigmoid colon.
Khalil, SN; Marcus, MA; Nuutinen, LS; Rawal, N; Stanley, TH; van Haaren, ER, 1991
)
0.77
"In a small clinical trial, a new therapeutic approach was studied, whether naloxone, in high dosage over a prolonged period of time, will attenuate withdrawal symptoms in acute opiate detoxification."( Continuous naloxone administration suppresses opiate withdrawal symptoms in human opiate addicts during detoxification treatment.
Lenz, K; Loimer, N; Presslich, O; Schmid, RW, 1989
)
0.28
"The induction dose-response of midazolam was compared with the dose-response of its combination with methohexitone sodium and with that of methohexitone alone."( Midazolam acts synergistically with methohexitone for induction of anaesthesia.
Ben-Shlomo, I; Ezry, J; Finger, J; Fleyshman, G; Tverskoy, M, 1989
)
0.28
" When alpha-(+/-)-5-allyl-1-methyl-5-(1-methyl-2-pentinyl) barbituric acid (methohexital) was added to the incubation medium of the neuroblastoma cells, a dose-dependent increase in soluble hexokinase activity was measurable, whereas the glucose-6-phosphate level was decreased at least within a therapeutically relevant dosage range of the anesthetic."( Effect of methohexital on the relationship between hexokinase distribution and energy metabolism in neuroblastoma cells.
Krieglstein, J; Mwasekaga, S, 1987
)
0.9
" Spontaneous ventilation is possible with the lesser dosage of fentanyl."( [Anesthesia with perfused methohexital-fentanyl combination].
Alegria, D; Ancelin, P; Bourdé, MC; Chauvin, G; Texereau, P,
)
0.43
"Alfentanil in combination with etomidate and N2O/O2 was given to 50 patients as single dosage (0."( [Alfentanil in routine clinical use. A study of 50 patients].
Löffler, B, 1985
)
0.27
" The dosage of etomidate and methohexitone was lowe than that reported in the literature."( [Etomidate versus methohexital for intravenous anesthesia with alfentanyl and nitrous oxide-oxygen. A double-blind study of circulatory behavior and postoperative course].
Papst-Baierl, D; Sold, M; Weis, KH, 1985
)
0.6
" 5 Methohexitone and thiopentone produced a biphasic dose-response on the K+-stimulated release of both amino acids; low concentrations enhanced release, high concentrations depressed release."( The effects of anaesthetics on the uptake and release of amino acid neurotransmitters in thalamic slices.
Kendall, TJ; Minchin, MC, 1982
)
0.26
" In animals initially anesthetized with pentobarbital, delta-9-THC over a wide dosage range produced only an enhancement of the reflex, whereas in methohexital-treated animals only depression was elicited."( Influence of different barbiturate anesthetics on delta-9-tetrahydrocannabinol effects on spinal monosynaptic reflexes.
Karler, R; Turkanis, SA, 1983
)
0.47
"To induce anaesthesia, 100 children between 18 months and 7 years of age who had been selected for surgery or invasive diagnosis, received a 10% methohexitone solution in a dosage of 20-30 mg/kg body weight by rectal instillation."( [Methohexital for rectal anesthetic induction in children].
Kraus, G; Taeger, K, 1982
)
1.17
"The dose-response relationship of commercially available preparations of methohexital, pentobarbital, phenobarbital, and thiopental and their respective drug-free solutions on granulocyte function was investigated to evaluate whether suppression of neutrophil chemiluminescence is mediated by the barbiturates themselves or by their drug-free solutions."( Do barbiturates impair zymosan-induced granulocyte function?
Birkhahn, A; Buhl, R; Mirow, N; Schneider, M; Weiss, M; Wernet, P, 1994
)
0.52
"The dose-response effects of the four barbiturates on granulocyte function were tested by zymosan-induced neutrophil chemiluminescence and, in addition, in a cell-free chemiluminescence system."( Do barbiturates impair zymosan-induced granulocyte function?
Birkhahn, A; Buhl, R; Mirow, N; Schneider, M; Weiss, M; Wernet, P, 1994
)
0.29
"The dose-response relationship of four commercially available barbiturates (methohexitone, pentobarbitone, phenobarbitone and thiopentone) and of their drug-free solutions on the production of oxygen radicals by neutrophils were tested by N-formylmethionyl-leucyl-phenylalanine (FMLP)-induced granulocyte chemiluminescence and in a cell-free chemiluminescence system."( Do barbiturates and their solutions suppress FMLP-induced neutrophil chemiluminescence?
Birkhahn, A; Buhl, R; Mirow, N; Schneider, M; Weiss, M; Wernet, P, 1994
)
0.29
" These findings have implications for electrical dosing in right unilateral ECT."( Possible impact of stimulus duration on seizure threshold in ECT.
Jarvis, MR; Rasmussen, KG; Zorumski, CF, 1994
)
0.29
" Mechanical difficulties such as trouble gaining intravenous access and medicinal problems such as inappropriate dosing were rare."( Procedural complications of electroconvulsive therapy: assessment and recommendations.
Haas, S; Lippmann, S; Quast, G, 1993
)
0.29
" Anaesthesic efficacy of this gel was performed in 11 patients receiving a therapeutic dosage (25 mg/kg)."( [Pharmacokinetic and clinical evaluation of rectal hydrophilic gel of methohexital in pediatric surgery].
Benoit, I; Grellet, J; Merlet, JP; Meynat, Y; Michel-Guéroult, P; Saux, MC,
)
0.37
" Dosage requirements to reach the initial sedation end points of slurred speech and ptosis of eyelids vary widely from one patient to another."( Multidrug intravenous sedation: determinants of the sedative dose of midazolam.
Finder, RL; Jackson, DL; Moore, PA, 1997
)
0.3
"An assessment of physical, cardiovascular, behavioral, and pharmacologic factors that might predict midazolam dosage requirements for the initial sedation titration was carried out with data collected from a large controlled clinical trial of fentanyl, midazolam, and methohexital sedation for third molar surgery."( Multidrug intravenous sedation: determinants of the sedative dose of midazolam.
Finder, RL; Jackson, DL; Moore, PA, 1997
)
0.48
" The direct cost of methohexital was lower than that of propofol, based on the milligram dosage infused during the operation."( The cost-effectiveness of methohexital versus propofol for sedation during monitored anesthesia care.
Inagaki, Y; Sá Rêgo, MM; White, PF, 1999
)
0.93
"The dosage of methohexitone (methohexital) administered by anesthetic staff was surveyed in a consecutive series of 52 patients referred for electroconvulsive therapy (ECT) in routine clinical practice in Edinburgh."( A survey of methohexitone use by anesthetists in the clinical practice of ECT in Edinburgh.
Cook, A; Scott, AI; Stevenson, G, 2000
)
0.6
"Methohexital for ECT showed a great variability, exceeding as well as undershooting the dosage recommendations widely."( Bispectral index-controlled anaesthesia for electroconvulsive therapy.
Bauer, M; Bein, B; Buttgereit, B; Goeder, R; Hanss, R; Scholz, J; Schulz-Du Bois, AC; Steinfath, M, 2006
)
1.78
" Both sedatives were administered over 7 days and individual dosage was adapted according to clinical requirements."( Effects of propofol vs methohexital on neutrophil function and immune status in critically ill patients.
Hout, Nv; Huettemann, E; Jung, A; Sakka, SG; Vogelsang, H, 2006
)
0.64
" Therefore, we tested the dose-response direct cardiac effects of clinically available induction agents in an isolated septic rat heart model."( Cardiac effects of induction agents in the septic rat heart.
Busse, H; Graf, BM; Lunz, D; Sinner, B; Zausig, YA; Zink, W, 2009
)
0.35
" Despite adequate dosing of both intravenous and inhalation anesthetics, our patient was resistant to induction of the state of general anesthesia."( Hyperlipidemia sink for anesthetic agents.
Eldesouki, E; Hobika, GG; Johnson, TJ; Nader, ND; Porhomayon, J; Smith, K, 2016
)
0.43
" Inclusion criteria were the use of etomidate and/or methohexital and documentation of dosage, electroconvulsive therapy dosage and seizure duration."( The influence of anaesthetic choice on seizure duration of electroconvulsive therapy; etomidate versus methohexital.
Ahmadi, M; Chomrikh, L; Koopman, SJHA; Kuijper, TM; van der Vlugt, JJB, 2022
)
1.19
[information is derived through text-mining from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Roles (2)

RoleDescription
intravenous anaestheticnull
drug allergenAny drug which causes the onset of an allergic reaction.
[role information is derived from Chemical Entities of Biological Interest (ChEBI), Hastings J, Owen G, Dekker A, Ennis M, Kale N, Muthukrishnan V, Turner S, Swainston N, Mendes P, Steinbeck C. (2016). ChEBI in 2016: Improved services and an expanding collection of metabolites. Nucleic Acids Res]

Drug Classes (2)

ClassDescription
barbituratesMembers of the class of pyrimidones consisting of pyrimidine-2,4,6(1H,3H,5H)-trione (barbituric acid) and its derivatives. Largest group of the synthetic sedative/hypnotics, sharing a characteristic six-membered ring structure.
acetylenic compoundAny organic molecule containing a C#C bond.
[compound class information is derived from Chemical Entities of Biological Interest (ChEBI), Hastings J, Owen G, Dekker A, Ennis M, Kale N, Muthukrishnan V, Turner S, Swainston N, Mendes P, Steinbeck C. (2016). ChEBI in 2016: Improved services and an expanding collection of metabolites. Nucleic Acids Res]

Bioassays (54)

Assay IDTitleYearJournalArticle
AID1474166Liver toxicity in human assessed as induction of drug-induced liver injury by measuring severity class index2016Drug discovery today, Apr, Volume: 21, Issue:4
DILIrank: the largest reference drug list ranked by the risk for developing drug-induced liver injury in humans.
AID1079942Steatosis, proven histopathologically. Value is number of references indexed. [column 'STEAT' in source]
AID588218FDA HLAED, lactate dehydrogenase (LDH) increase2004Current drug discovery technologies, Dec, Volume: 1, Issue:4
Assessment of the health effects of chemicals in humans: II. Construction of an adverse effects database for QSAR modeling.
AID588215FDA HLAED, alkaline phosphatase increase2004Current drug discovery technologies, Dec, Volume: 1, Issue:4
Assessment of the health effects of chemicals in humans: II. Construction of an adverse effects database for QSAR modeling.
AID625292Drug Induced Liver Injury Prediction System (DILIps) training set; hepatic side effect (HepSE) combined score2011PLoS computational biology, Dec, Volume: 7, Issue:12
Translating clinical findings into knowledge in drug safety evaluation--drug induced liver injury prediction system (DILIps).
AID1079932Highest frequency of moderate liver toxicity observed during clinical trials, expressed as a percentage. [column '% BIOL' in source]
AID1079948Times to onset, minimal and maximal, observed in the indexed observations. [column 'DELAI' in source]
AID625282Drug Induced Liver Injury Prediction System (DILIps) training set; hepatic side effect (HepSE) score for cirrhosis2011PLoS computational biology, Dec, Volume: 7, Issue:12
Translating clinical findings into knowledge in drug safety evaluation--drug induced liver injury prediction system (DILIps).
AID588216FDA HLAED, serum glutamic oxaloacetic transaminase (SGOT) increase2004Current drug discovery technologies, Dec, Volume: 1, Issue:4
Assessment of the health effects of chemicals in humans: II. Construction of an adverse effects database for QSAR modeling.
AID38744Negative log of molar concentration (-log ED50) required to reduce cell division by 50% in Arbacia egg; ND = No Data1983Journal of medicinal chemistry, Jul, Volume: 26, Issue:7
A simplified high-pressure liquid chromatography method for determining lipophilicity for structure-activity relationships.
AID588219FDA HLAED, gamma-glutamyl transferase (GGT) increase2004Current drug discovery technologies, Dec, Volume: 1, Issue:4
Assessment of the health effects of chemicals in humans: II. Construction of an adverse effects database for QSAR modeling.
AID625286Drug Induced Liver Injury Prediction System (DILIps) training set; hepatic side effect (HepSE) score for hepatitis2011PLoS computational biology, Dec, Volume: 7, Issue:12
Translating clinical findings into knowledge in drug safety evaluation--drug induced liver injury prediction system (DILIps).
AID625279Drug Induced Liver Injury Prediction System (DILIps) training set; hepatic side effect (HepSE) score for bilirubinemia2011PLoS computational biology, Dec, Volume: 7, Issue:12
Translating clinical findings into knowledge in drug safety evaluation--drug induced liver injury prediction system (DILIps).
AID540210Clearance in human after iv administration2008Drug metabolism and disposition: the biological fate of chemicals, Jul, Volume: 36, Issue:7
Trend analysis of a database of intravenous pharmacokinetic parameters in humans for 670 drug compounds.
AID1079946Presence of at least one case with successful reintroduction. [column 'REINT' in source]
AID625281Drug Induced Liver Injury Prediction System (DILIps) training set; hepatic side effect (HepSE) score for cholelithiasis2011PLoS computational biology, Dec, Volume: 7, Issue:12
Translating clinical findings into knowledge in drug safety evaluation--drug induced liver injury prediction system (DILIps).
AID588217FDA HLAED, serum glutamic pyruvic transaminase (SGPT) increase2004Current drug discovery technologies, Dec, Volume: 1, Issue:4
Assessment of the health effects of chemicals in humans: II. Construction of an adverse effects database for QSAR modeling.
AID625291Drug Induced Liver Injury Prediction System (DILIps) training set; hepatic side effect (HepSE) score for liver function tests abnormal2011PLoS computational biology, Dec, Volume: 7, Issue:12
Translating clinical findings into knowledge in drug safety evaluation--drug induced liver injury prediction system (DILIps).
AID588214FDA HLAED, liver enzyme composite activity2004Current drug discovery technologies, Dec, Volume: 1, Issue:4
Assessment of the health effects of chemicals in humans: II. Construction of an adverse effects database for QSAR modeling.
AID1079940Granulomatous liver disease, proven histopathologically. Value is number of references indexed. [column 'GRAN' in source]
AID540212Mean residence time in human after iv administration2008Drug metabolism and disposition: the biological fate of chemicals, Jul, Volume: 36, Issue:7
Trend analysis of a database of intravenous pharmacokinetic parameters in humans for 670 drug compounds.
AID540213Half life in human after iv administration2008Drug metabolism and disposition: the biological fate of chemicals, Jul, Volume: 36, Issue:7
Trend analysis of a database of intravenous pharmacokinetic parameters in humans for 670 drug compounds.
AID540211Fraction unbound in human after iv administration2008Drug metabolism and disposition: the biological fate of chemicals, Jul, Volume: 36, Issue:7
Trend analysis of a database of intravenous pharmacokinetic parameters in humans for 670 drug compounds.
AID625285Drug Induced Liver Injury Prediction System (DILIps) training set; hepatic side effect (HepSE) score for hepatic necrosis2011PLoS computational biology, Dec, Volume: 7, Issue:12
Translating clinical findings into knowledge in drug safety evaluation--drug induced liver injury prediction system (DILIps).
AID1130944Hypnotic activity in rabbit1979Journal of medicinal chemistry, Nov, Volume: 22, Issue:11
Correlation of biological activity and high-pressure liquid chromatographic retention index for a series of propranolol, barbiturate, and anthranilic acid analogues.
AID1079937Severe hepatitis, defined as possibly life-threatening liver failure or through clinical observations. Value is number of references indexed. [column 'MASS' in source]
AID625290Drug Induced Liver Injury Prediction System (DILIps) training set; hepatic side effect (HepSE) score for liver fatty2011PLoS computational biology, Dec, Volume: 7, Issue:12
Translating clinical findings into knowledge in drug safety evaluation--drug induced liver injury prediction system (DILIps).
AID1079934Highest frequency of acute liver toxicity observed during clinical trials, expressed as a percentage. [column '% AIGUE' in source]
AID1130943Octanol-water partition coefficient, log P of nonionized form of compound1979Journal of medicinal chemistry, Nov, Volume: 22, Issue:11
Correlation of biological activity and high-pressure liquid chromatographic retention index for a series of propranolol, barbiturate, and anthranilic acid analogues.
AID1079944Benign tumor, proven histopathologically. Value is number of references indexed. [column 'T.BEN' in source]
AID1079936Choleostatic liver toxicity, either proven histopathologically or where the ratio of maximal ALT or AST activity above normal to that of Alkaline Phosphatase is < 2 (see ACUTE). Value is number of references indexed. [column 'CHOLE' in source]
AID625284Drug Induced Liver Injury Prediction System (DILIps) training set; hepatic side effect (HepSE) score for hepatic failure2011PLoS computational biology, Dec, Volume: 7, Issue:12
Translating clinical findings into knowledge in drug safety evaluation--drug induced liver injury prediction system (DILIps).
AID1079943Malignant tumor, proven histopathologically. Value is number of references indexed. [column 'T.MAL' in source]
AID169098Negative log of molar concentration (-log C) required to produce 50% inhibition of oxygen (oxygen uptake) on rat brain respiration in vitro; ND = No Data1983Journal of medicinal chemistry, Jul, Volume: 26, Issue:7
A simplified high-pressure liquid chromatography method for determining lipophilicity for structure-activity relationships.
AID625283Drug Induced Liver Injury Prediction System (DILIps) training set; hepatic side effect (HepSE) score for elevated liver function tests2011PLoS computational biology, Dec, Volume: 7, Issue:12
Translating clinical findings into knowledge in drug safety evaluation--drug induced liver injury prediction system (DILIps).
AID1079939Cirrhosis, proven histopathologically. Value is number of references indexed. [column 'CIRRH' in source]
AID1474167Liver toxicity in human assessed as induction of drug-induced liver injury by measuring verified drug-induced liver injury concern status2016Drug discovery today, Apr, Volume: 21, Issue:4
DILIrank: the largest reference drug list ranked by the risk for developing drug-induced liver injury in humans.
AID540209Volume of distribution at steady state in human after iv administration2008Drug metabolism and disposition: the biological fate of chemicals, Jul, Volume: 36, Issue:7
Trend analysis of a database of intravenous pharmacokinetic parameters in humans for 670 drug compounds.
AID1079933Acute liver toxicity defined via clinical observations and clear clinical-chemistry results: serum ALT or AST activity > 6 N or serum alkaline phosphatases activity > 1.7 N. This category includes cytolytic, choleostatic and mixed liver toxicity. Value is
AID625288Drug Induced Liver Injury Prediction System (DILIps) training set; hepatic side effect (HepSE) score for jaundice2011PLoS computational biology, Dec, Volume: 7, Issue:12
Translating clinical findings into knowledge in drug safety evaluation--drug induced liver injury prediction system (DILIps).
AID625287Drug Induced Liver Injury Prediction System (DILIps) training set; hepatic side effect (HepSE) score for hepatomegaly2011PLoS computational biology, Dec, Volume: 7, Issue:12
Translating clinical findings into knowledge in drug safety evaluation--drug induced liver injury prediction system (DILIps).
AID1079935Cytolytic liver toxicity, either proven histopathologically or where the ratio of maximal ALT or AST activity above normal to that of Alkaline Phosphatase is > 5 (see ACUTE). Value is number of references indexed. [column 'CYTOL' in source]
AID1079931Moderate liver toxicity, defined via clinical-chemistry results: ALT or AST serum activity 6 times the normal upper limit (N) or alkaline phosphatase serum activity of 1.7 N. Value is number of references indexed. [column 'BIOL' in source]
AID625289Drug Induced Liver Injury Prediction System (DILIps) training set; hepatic side effect (HepSE) score for liver disease2011PLoS computational biology, Dec, Volume: 7, Issue:12
Translating clinical findings into knowledge in drug safety evaluation--drug induced liver injury prediction system (DILIps).
AID1079938Chronic liver disease either proven histopathologically, or through a chonic elevation of serum amino-transferase activity after 6 months. Value is number of references indexed. [column 'CHRON' in source]
AID1079949Proposed mechanism(s) of liver damage. [column 'MEC' in source]
AID1079947Comments (NB not yet translated). [column 'COMMENTAIRES' in source]
AID26320pKa value is evaluated1983Journal of medicinal chemistry, Jul, Volume: 26, Issue:7
A simplified high-pressure liquid chromatography method for determining lipophilicity for structure-activity relationships.
AID167610Negative log of minimum effective dose (moles per kilogram) in rabbits (hypnotic)1983Journal of medicinal chemistry, Jul, Volume: 26, Issue:7
A simplified high-pressure liquid chromatography method for determining lipophilicity for structure-activity relationships.
AID1079941Liver damage due to vascular disease: peliosis hepatitis, hepatic veno-occlusive disease, Budd-Chiari syndrome. Value is number of references indexed. [column 'VASC' in source]
AID1079945Animal toxicity known. [column 'TOXIC' in source]
AID24211Compound is evaluated for ionization constant log k1983Journal of medicinal chemistry, Jul, Volume: 26, Issue:7
A simplified high-pressure liquid chromatography method for determining lipophilicity for structure-activity relationships.
AID625280Drug Induced Liver Injury Prediction System (DILIps) training set; hepatic side effect (HepSE) score for cholecystitis2011PLoS computational biology, Dec, Volume: 7, Issue:12
Translating clinical findings into knowledge in drug safety evaluation--drug induced liver injury prediction system (DILIps).
AID1130940Retention index of the compound by HPLC method1979Journal of medicinal chemistry, Nov, Volume: 22, Issue:11
Correlation of biological activity and high-pressure liquid chromatographic retention index for a series of propranolol, barbiturate, and anthranilic acid analogues.
[information is prepared from bioassay data collected from National Library of Medicine (NLM), extracted Dec-2023]

Research

Studies (1,420)

TimeframeStudies, This Drug (%)All Drugs %
pre-19901010 (71.13)18.7374
1990's250 (17.61)18.2507
2000's105 (7.39)29.6817
2010's42 (2.96)24.3611
2020's13 (0.92)2.80
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Market Indicators

Research Demand Index: 53.66

According to the monthly volume, diversity, and competition of internet searches for this compound, as well the volume and growth of publications, there is estimated to be very strong demand-to-supply ratio for research on this compound.

MetricThis Compound (vs All)
Research Demand Index53.66 (24.57)
Research Supply Index7.50 (2.92)
Research Growth Index4.15 (4.65)
Search Engine Demand Index91.11 (26.88)
Search Engine Supply Index2.00 (0.95)

This Compound (53.66)

All Compounds (24.57)

Study Types

Publication TypeThis drug (%)All Drugs (%)
Trials261 (16.94%)5.53%
Reviews46 (2.99%)6.00%
Case Studies64 (4.15%)4.05%
Observational4 (0.26%)0.25%
Other1,166 (75.67%)84.16%
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Clinical Trials (10)

Trial Overview

TrialPhaseEnrollmentStudy TypeStart DateStatus
Comparing Therapeutic Efficacy and Cognitive Side Effects of Electroconvulsive Therapy (ECT) Using Ketamine Versus Methohexital Anesthesia [NCT01881763]Phase 431 participants (Actual)Interventional2010-06-30Completed
Comparison of Methohexital With Propofol for Anesthetic Induction in Patients Treated With an Antagonist of the Renin-Angiotensin System. [NCT02624050]51 participants (Actual)Interventional2016-08-01Completed
Comparison of Bolus Dosing of Methohexital and Propofol in Elective Direct Current Cardioversion [NCT04187196]Phase 473 participants (Actual)Interventional2020-04-29Completed
A Randomized Comparison of Ketamine and Methohexital Anesthesia for Electroconvulsive Therapy (ECT) in Depression [NCT01367119]38 participants (Actual)Interventional2011-05-31Completed
Ketamine vs. Methohexital Anesthesia for Improvement of Major Depressive Disorder in Electroconvulsive Therapy [NCT02752724]52 participants (Actual)Interventional2016-03-31Completed
A Prospective Randomized, Double Blind, Controlled, Safety and Non-inferiority Study of Esketamine Plus Propofol Compared to Methohexital Anesthesia for Electroconvulsive Therapy [NCT05655754]Phase 4100 participants (Anticipated)Interventional2022-11-01Recruiting
Ketamine Anesthesia to Enhance Efficacy and Tolerability of Electroconvulsive Therapy in Patients With Unipolar or Bipolar Depression [NCT01309581]3 participants (Actual)Interventional2010-04-30Terminated(stopped due to limited enrollment)
A Randomized Pilot Study Examining DCEEG Characteristics in Ketamine Versus Methohexital Induction in Depressed Patients Receiving Electroconvulsive Therapy [NCT04022226]Early Phase 111 participants (Actual)Interventional2019-10-01Completed
A Randomised Controlled Trial of Standard Bilateral Electroconvulsive Therapy Versus High-dose Unilateral Electroconvulsive Therapy for Severe Depression [NCT01907217]Phase 4138 participants (Actual)Interventional2008-05-31Completed
The Use of Ketamine Versus Methohexital for Electroconvulsive Therapy: A Cross-Over Comparative Study on Patient Recovery and Re-Orientation Time [NCT01567852]20 participants (Actual)Interventional2011-08-31Completed
[information is prepared from clinicaltrials.gov, extracted Sep-2024]

Trial Outcomes

TrialOutcome
NCT01367119 (3) [back to overview]Mean Post Anesthesia Recovery Side Effects
NCT01367119 (3) [back to overview]Mean Depression Rating Using the Patient Health Questionnaire-9 (PHQ-9)
NCT01367119 (3) [back to overview]Mean Depression Rating Using the Hospital Anxiety and Depression Scale (HADS)
NCT01567852 (2) [back to overview]Recovery Time
NCT01567852 (2) [back to overview]Re-orientation Time
NCT01881763 (1) [back to overview]Hamilton Rating Scale for Depression (HRSD) Improvement
NCT01907217 (4) [back to overview]Columbia Autobiographical Memory Interview-Short Form (AMI-SF)
NCT01907217 (4) [back to overview]Columbia Autobiographical Memory Interview-Short Form (AMI-SF)
NCT01907217 (4) [back to overview]Columbia Autobiographical Memory Interview-Short Form (AMI-SF)
NCT01907217 (4) [back to overview]Hamilton Depression Rating Scale (HDRS)
NCT02624050 (11) [back to overview]Diastolic Blood Pressure
NCT02624050 (11) [back to overview]Duration of Each Hypotension Episode
NCT02624050 (11) [back to overview]Heart Rate
NCT02624050 (11) [back to overview]Number of Participants Who Had Hypotensive Events
NCT02624050 (11) [back to overview]Number of Participants With Refractory Hypotension
NCT02624050 (11) [back to overview]Systolic Blood Pressure
NCT02624050 (11) [back to overview]Blood Levels of Angiotensin II (AII) (at Baseline (Time 0) and 3,5,10 and 15 Min After Anesthetic Induction)
NCT02624050 (11) [back to overview]Blood Levels of Arginine Vasopressin (AVP) (at Baseline (Time 0) and 3,5,10 and 15 Min After Anesthetic Induction) for Participants Who Did Not Receive AVP for Refractory Hypotension
NCT02624050 (11) [back to overview]Blood Levels of AVP (at Baseline (Time 0) and 3,5,10 and 15 Min) for Participants Who Received AVP for Refractory Hypotension
NCT02624050 (11) [back to overview]Blood Levels of Epinephrine (at Baseline (Time 0) and 3,5,10 and 15 Min After Induction of Anesthesia)
NCT02624050 (11) [back to overview]Serum Concentration of Norepinephrine (NE) (at Baseline (Time 0) and 3,5,10 and 15 Min After Anesthetic Induction)
NCT04187196 (12) [back to overview]Time to First Electrical Direct-current Shock
NCT04187196 (12) [back to overview]Diastolic Blood Pressure
NCT04187196 (12) [back to overview]Heart Rate
NCT04187196 (12) [back to overview]Mean Arterial Blood Pressure
NCT04187196 (12) [back to overview]Respiratory Rate
NCT04187196 (12) [back to overview]Saturation of Peripheral Oxygen (SpO2)
NCT04187196 (12) [back to overview]Systolic Blood Pressure
NCT04187196 (12) [back to overview]Time From Initiation of Sedation to Full Recovery
NCT04187196 (12) [back to overview]Time From End of Injection to Loss of Conscious
NCT04187196 (12) [back to overview]Recall of Pain at Injection Site - Visual Analog Scale
NCT04187196 (12) [back to overview]Recall of Anything Unpleasant About the Procedure - Visual Analog Scale
NCT04187196 (12) [back to overview]Time to Eyes Opening

Mean Post Anesthesia Recovery Side Effects

Post anesthesia recovery side effects were assessed at the time of discharge from recovery with five patient self-report items: nausea, headache, myalgia, visual disturbance, and confusion. These were rated by the patients on a four point scale (0, 1, 2, 3) - absent, mild, moderate, severe. This means that for each item a subject could score between 0 (no symptoms) and 3 (severe symptoms). Also, degree of recovery room agitation was rated by the nurse on a similar four point scale. (NCT01367119)
Timeframe: Time of discharge from recovery after ECT for each treatment, approximately 30 minutes after the end of the seizure

,
Interventionunits on a scale (Mean)
NauseaHeadacheMyalgiaVisual DisturbanceConfusionRecovery Room Agitation
Ketamine0.120.290.070.080.700.07
Methohexital0.150.350.150.010.300.09

[back to top]

Mean Depression Rating Using the Patient Health Questionnaire-9 (PHQ-9)

"The PHQ-9 is the nine item depression scale of the Patient Health Questionnaire. The PHQ-9 is based directly on the diagnostic criteria for major depressive disorder in the Diagnostic and Statistical Manual Fourth Edition (DSM-IV). Each item on the questionnaire is scored from 0-3 and this means that a person can score between 0 (no symptoms) and 27 (severe symptoms) for depression.~The questionnaire was administered to the subjects prior to the first treatment, the morning of the third treatment, the morning of the fifth treatment, and the morning of the seventh treatment. For subjects whos treatment series ws cancelled prior to a scheduled next administration of the rating scale, every effort was mde to administer them 2 days after the last treatment.~Means are reported overall across all treatments; p-values also take into account variability across treatments and within subject." (NCT01367119)
Timeframe: Baseline and after every second treatment for 7 treatments

Interventionunits on a scale (Mean)
Ketamine15.98
Methohexital17.57

[back to top]

Mean Depression Rating Using the Hospital Anxiety and Depression Scale (HADS)

"The HADS is a fourteen item scale. Seven of the items relate to anxiety and seven relate to depression. Each item on the questionnaire is scored from 0-3 and this means that a person can score between 0 (no symptoms) and 42 (severe symptoms) for either anxiety or depression.~The questionnaire was administered to the subjects prior to the first treatment, the morning of the third treatment, the morning of the fifth treatment, and the morning of the seventh treatment. For subjects whose treatment series ws cancelled prior to a scheduled next administration of the rating scale, every effort was made to administer them 2 days after the last treatment.~Means are reported overall across all treatments; p-values also take into account variability across treatments and within subject." (NCT01367119)
Timeframe: Baseline and after every second treatment for 7 treatments

Interventionunits on a scale (Mean)
Ketamine22.08
Methohexital24.45

[back to top]

Recovery Time

Recovery was assessed using 5 criteria (blood pressure, voluntary movement, oxygen requirement, consciousness, respiratory effort). Each criteria was scored from 0-2, with a full score of 10. The patient is scored at baseline, and is deemed recovered when all criteria has reached baseline score again. (NCT01567852)
Timeframe: 1 hour

Interventionminutes (Mean)
Ketamine Inductions28.6
Methohexital Inductions27.2

[back to top]

Re-orientation Time

Patients will be scored based on 5 questions (name, age, year, day of week, location). Each patient will be scored prior to induction as to how many questions they score correctly. Patient is deemed re-oriented when they score the same as baseline after the treatment. (NCT01567852)
Timeframe: 1 hour

Interventionminutes (Mean)
Ketamine Inductions24.5
Methohexital Inductions19.5

[back to top]

Hamilton Rating Scale for Depression (HRSD) Improvement

The items mostly range from a score of 0-4 but there are some questions that range from a score of 0-2. The maximum total score that can be reported is 76 and the lowest score is 0. Higher values represent a worse outcome. Items are summed together to compute the total score. Remission is defined as two consecutive Hamilton Rating Scale for Depression, 24 items (HRSD-24) scores < 10, and HRSD-24 total score does not increase > 3 points on the second consecutive HRSD-24, or remains < 6 at the last two consecutive treatments. HRSD-24 scores are used to define remission. (NCT01881763)
Timeframe: Days required to achieve remission (on average 3-4 weeks)

InterventionHRSD units (Mean)
Ketamine7.82
Methohexital8.60

[back to top]

Columbia Autobiographical Memory Interview-Short Form (AMI-SF)

The AMI-SF is used to assess retrospective autobiographical memory function. It has six categories, which involve five questions each, about a family member, most recent travel, last New Year's Eve, last birthday, most recent employment and last visit to a doctor for a physical complaint. At baseline interviewers encourage the participant to recall as much information as they can. Responses at baseline can be scored either two points, for a recognisable real memory, or zero for no memory or too little information to constitute a proper memory. Only those questions for which a memory had been retrieved at baseline are examined at follow-up. Follow-up assessments are scored as percentage recall of baseline score, which is scored as 100% irrespective of actual performance.. (NCT01907217)
Timeframe: 3 months follow-up

Intervention% of baseline performance (Mean)
Bilateral ECT Mecta 5000M56.2
High-dose Unilateral ECT Mecta 5000M67.3

[back to top]

Columbia Autobiographical Memory Interview-Short Form (AMI-SF)

The AMI-SF is used to assess retrospective autobiographical memory function. It has six categories, which involve five questions each, about a family member, most recent travel, last New Year's Eve, last birthday, most recent employment and last visit to a doctor for a physical complaint. At baseline interviewers encourage the participant to recall as much information as they can. Responses at baseline can be scored either two points, for a recognisable real memory, or zero for no memory or too little information to constitute a proper memory. Only those questions for which a memory had been retrieved at baseline are examined at follow-up. Follow-up assessments are scored as percentage recall of baseline score, which is scored as 100% irrespective of actual performance.. (NCT01907217)
Timeframe: 6 months follow-up

Intervention% of baseline performance (Mean)
Bilateral ECT Mecta 5000M52.9
High-dose Unilateral ECT Mecta 5000M63.4

[back to top]

Columbia Autobiographical Memory Interview-Short Form (AMI-SF)

The AMI-SF is used to assess retrospective autobiographical memory function. It has six categories, which involve five questions each, about a family member, most recent travel, last New Year's Eve, last birthday, most recent employment and last visit to a doctor for a physical complaint. At baseline interviewers encourage the participant to recall as much information as they can. Responses at baseline can be scored either two points, for a recognisable real memory, or zero for no memory or too little information to constitute a proper memory. Only those questions for which a memory had been retrieved at baseline are examined at follow-up. Follow-up assessments are scored as percentage recall of baseline score, which is scored as 100% irrespective of actual performance.. (NCT01907217)
Timeframe: end of allocated ECT course

Intervention% of baseline performance (Mean)
Bilateral ECT Mecta 5000M56.8
High-dose Unilateral ECT Mecta 5000M67.1

[back to top]

Hamilton Depression Rating Scale (HDRS)

The HDRS was originally designed to assess severity of depressive symptoms in patients with a primary depressive illness and is now the most commonly used measure of depression severity. It was first published in a 17-item format with the optional addition of 4 items making up the 21-item version. In addition to the original 21 items, the 24-item HDRS includes items on helplessness, hopelessness and worthlessness; its score range is 0-77, with higher scores reflecting greater burden of depressive symptoms. (NCT01907217)
Timeframe: HDRS scores were obtained at baseline, end of allocated ECT treatment, and at 3 and 6 month follow-up timepoints.

,
Interventionunits on a scale (Mean)
BaselineEnd-of-treatment3 months follow-up6 months follow-up
Bilateral ECT Mecta 5000M29.512.515.013.0
High-dose Unilateral ECT Mecta 5000M30.411.111.512.6

[back to top]

Diastolic Blood Pressure

Diastolic blood pressure will be measured through standard monitoring. (NCT02624050)
Timeframe: Hemodynamic measurements will be taken during the first 15 minutes of anesthetic induction

Interventionmm Hg (Mean)
Methohexital85
Propofol72

[back to top]

Duration of Each Hypotension Episode

This is the length of time that systolic blood pressure was either: (1) < 85 mmHg, or (2) a decrease of more than 30% from the individual's baseline SBP. (NCT02624050)
Timeframe: Hemodynamic measurements will be taken during the first 15 minutes of anesthetic induction

Interventionmin (Mean)
Methohexital5.1
Propofol4.8

[back to top]

Heart Rate

Heart rate will be measured through standard monitoring. (NCT02624050)
Timeframe: Hemodynamic measurements will be taken during the first 15 minutes of anesthetic induction

Interventionbpm (Mean)
Methohexital80
Propofol76

[back to top]

Number of Participants Who Had Hypotensive Events

Hypotensive events under either methohexital or propofol general anesthesia will be counted as the primary outcome measure (NCT02624050)
Timeframe: Hemodynamic measurements will be taken during the first 15 minutes of anesthetic induction

InterventionParticipants (Count of Participants)
Methohexital8
Propofol21

[back to top]

Number of Participants With Refractory Hypotension

Refractory hypotension is defined as a hypotensive event that continues after 3 doses of vasopressors (NCT02624050)
Timeframe: Hemodynamic measurements will be taken during the first 15 minutes of anesthetic induction

InterventionParticipants (Count of Participants)
Methohexital2
Propofol5

[back to top]

Systolic Blood Pressure

Systolic blood pressure will be measured through standard monitoring. (NCT02624050)
Timeframe: Hemodynamic measurements will be taken during the first 15 minutes of anesthetic induction

Interventionmm Hg (Mean)
Methohexital141
Propofol126

[back to top]

Blood Levels of Angiotensin II (AII) (at Baseline (Time 0) and 3,5,10 and 15 Min After Anesthetic Induction)

Serum concentrations of Angiotension II at predetermined time points (Baseline (Time 0) and 3,5,10 and 15 min) following anesthetic induction (NCT02624050)
Timeframe: Time 0,3,5,10 and 15 min following anesthetic induction

,
Interventionpg/ml (Mean)
Time 03 min5 min10 min15 min
Methohexital21.7119.0721.4224.4622.16
Propofol18.8519.5620.6220.3217.63

[back to top]

Blood Levels of Arginine Vasopressin (AVP) (at Baseline (Time 0) and 3,5,10 and 15 Min After Anesthetic Induction) for Participants Who Did Not Receive AVP for Refractory Hypotension

Serum concentrations of AVP at predetermined time points (Baseline (Time 0) and 3,5,10 and 15 min) following anesthetic induction determined for participants who did not receive AVP for refractory hypotension (NCT02624050)
Timeframe: Time 0,3,5,10 and 15 min following anesthetic induction

,
Interventionpg/ml (Mean)
Time 03 min5 min10 min15 min
Methohexital30.7525.0734.6629.3626.76
Propofol29.7626.5023.9916.3722.15

[back to top]

Blood Levels of AVP (at Baseline (Time 0) and 3,5,10 and 15 Min) for Participants Who Received AVP for Refractory Hypotension

Serum concentrations of AVP at predetermined time points (Baseline (Time 0) and 3,5,10 and 15 min), following anesthetic induction, determined for Participants who did not receive AVP for refractory hypotension (NCT02624050)
Timeframe: Time 0,3,5,10 and 15 min following anesthetic induction

,
Interventionpg/ml (Mean)
Time 03 min5 min10 min15 min
Methohexital14.8510.5713.7313.9312.85
Propofol33.2830.2429.8922.6163.86

[back to top]

Blood Levels of Epinephrine (at Baseline (Time 0) and 3,5,10 and 15 Min After Induction of Anesthesia)

Serum concentrations of Epinephrine at predetermined time points (Baseline (Time 0) and 3,5,10 and 15 min) following anesthetic induction (NCT02624050)
Timeframe: Time 0,3,5,10 and 15 min following anesthetic induction

,
Interventionpg/ml (Mean)
Time 03 min5 min10 min15 min
Methohexital70.8960.8689.8540.9646.28
Propofol66.4649.8757.2944.1739.56

[back to top]

Serum Concentration of Norepinephrine (NE) (at Baseline (Time 0) and 3,5,10 and 15 Min After Anesthetic Induction)

Serum concentrations of NE at predetermined time points (Baseline (Time 0) and 3,5,10 and 15 min) following anesthetic induction (NCT02624050)
Timeframe: Time 0,3,5,10 and 15 min following anesthetic induction

,
Interventionpg/ml (Mean)
Time 03 min5 min10 min15 min
Methohexital205.68175.24212.34179.42173.25
Propofol200.59166.04208.93168.39147.32

[back to top]

Time to First Electrical Direct-current Shock

Recorded in seconds. (NCT04187196)
Timeframe: Day 1

Interventionseconds (Median)
Sedation With Propofol Group1.28
Sedation With Methohexital Group1.2

[back to top]

Diastolic Blood Pressure

(NCT04187196)
Timeframe: Day 1: at induction, prior to first shock, and 1 minute, 3 minutes, 5 minutes, 7 minutes, 9 minutes, 10 minutes, 15 minutes, 20 minutes and 30 minutes after first cardioversion

,
InterventionmmHg (Median)
at inductionprior to first shock1 minute after first cardioversion3 minutes after first cardioversion5 minutes after first cardioversion7 minutes after first cardioversion9 minutes after first cardioversion10 minutes after first cardioversion15 minutes after first cardioversion20 minutes after first cardioversion30 minutes after first cardioversion
Sedation With Methohexital Group79.581.5767473726868696667
Sedation With Propofol Group7882706565636067656667

[back to top]

Heart Rate

(NCT04187196)
Timeframe: Day 1: at induction, prior to first shock, and 1 minute, 3 minutes, 5 minutes, 7 minutes, 9 minutes, 10 minutes, 15 minutes, 20 minutes and 30 minutes after first cardioversion

,
Interventionbeats per minute (Median)
at inductionprior to first shock1 minute after first cardioversion3 minutes after first cardioversion5 minutes after first cardioversion7 minutes after first cardioversion9 minutes after first cardioversion10 minutes after first cardioversion15 minutes after first cardioversion20 minutes after first cardioversion30 minutes after first cardioversion
Sedation With Methohexital Group939273.573.5696967.568686869
Sedation With Propofol Group9610069666966656464.562.565.5

[back to top]

Mean Arterial Blood Pressure

(NCT04187196)
Timeframe: Day 1: at induction, prior to first shock, and 1 minute, 3 minutes, 5 minutes, 7 minutes, 9 minutes, 10 minutes, 15 minutes, 20 minutes and 30 minutes after first cardioversion

,
InterventionmmHg (Median)
at inductionprior to first shock1 minute after first cardioversion3 minutes after first cardioversion5 minutes after first cardioversion7 minutes after first cardioversion9 minutes after first cardioversion10 minutes after first cardioversion15 minutes after first cardioversion20 minutes after first cardioversion30 minutes after first cardioversion
Sedation With Methohexital Group104.5104.5101.510410199.59594929293
Sedation With Propofol Group104102918684818184858687

[back to top]

Respiratory Rate

(NCT04187196)
Timeframe: Day 1: at induction, prior to first shock, and 1 minute, 3 minutes, 5 minutes, 7 minutes, 9 minutes, 10 minutes, 15 minutes, 20 minutes and 30 minutes after first cardioversion

,
Interventionnumber of breaths per minute (Median)
at inductionprior to first shock1 minute after first cardioversion3 minutes after first cardioversion5 minutes after first cardioversion7 minutes after first cardioversion9 minutes after first cardioversion10 minutes after first cardioversion15 minutes after first cardioversion20 minutes after first cardioversion30 minutes after first cardioversion
Sedation With Methohexital Group16.516.51719.518.519.51718171818
Sedation With Propofol Group1618171919191818181718

[back to top]

Saturation of Peripheral Oxygen (SpO2)

(NCT04187196)
Timeframe: Day 1: at induction, prior to first shock, and 1 minute, 3 minutes, 5 minutes, 7 minutes, 9 minutes, 10 minutes, 15 minutes, 20 minutes and 30 minutes after first cardioversion

,
Interventionpercentage of oxygen saturation (Median)
at inductionprior to first shock1 minute after first cardioversion3 minutes after first cardioversion5 minutes after first cardioversion7 minutes after first cardioversion9 minutes after first cardioversion10 minutes after first cardioversion15 minutes after first cardioversion20 minutes after first cardioversion30 minutes after first cardioversion
Sedation With Methohexital Group10010099.51001001001001001009998
Sedation With Propofol Group100100989999991001001009998

[back to top]

Systolic Blood Pressure

(NCT04187196)
Timeframe: Day 1: at induction, prior to first shock, and 1 minute, 3 minutes, 5 minutes, 7 minutes, 9 minutes, 10 minutes, 15 minutes, 20 minutes and 30 minutes after first cardioversion

,
InterventionmmHg (Median)
at inductionprior to first shock1 minute after first cardioversion3 minutes after first cardioversion5 minutes after first cardioversion7 minutes after first cardioversion9 minutes after first cardioversion10 minutes after first cardioversion15 minutes after first cardioversion20 minutes after first cardioversion
Sedation With Methohexital Group140144132140.5142.5139.5131136131127
Sedation With Propofol Group132138124122114111111113113116

[back to top]

Time From Initiation of Sedation to Full Recovery

"The time from initiation of sedation to full recovery Ramsay Sedation Scale (RSS) of 2 (RSS 2 means awake; cooperative, oriented, and tranquil.)-- as evidenced by the ability to answer the questions What is your name and what is your age? The timer will start at the initiation of induction. Recorded in minutes." (NCT04187196)
Timeframe: Day 1

Interventionminutes (Median)
Sedation With Propofol Group7.6
Sedation With Methohexital Group5.5

[back to top]

Time From End of Injection to Loss of Conscious

Recorded in minutes. (NCT04187196)
Timeframe: Day 1

Interventionminutes (Median)
Sedation With Propofol Group1.0
Sedation With Methohexital Group1.0

[back to top]

Recall of Pain at Injection Site - Visual Analog Scale

"These are 100 mm lines that are anchored with no pain on one end and worst imaginable pain on the other end. Total range 0-100, higher numbers correspond to worse pain." (NCT04187196)
Timeframe: Day 1

Interventionscore on a scale (Median)
Sedation With Propofol Group8
Sedation With Methohexital Group2

[back to top]

Recall of Anything Unpleasant About the Procedure - Visual Analog Scale

"These are 100 mm lines that are anchored with no distress on one end and worst imaginable distress on the other end. Total range 0-100, higher numbers correspond to worse distress." (NCT04187196)
Timeframe: Day 1

Interventionscore on a scale (Median)
Sedation With Propofol Group3
Sedation With Methohexital Group1

[back to top]

Time to Eyes Opening

Recorded in seconds. (NCT04187196)
Timeframe: Day 1

Interventionseconds (Median)
Sedation With Propofol Group7.0
Sedation With Methohexital Group4.2

[back to top]